RASL11B

Summary

RASL11B (RAS like family 11 member B, HGNC:23804) is a protein-coding gene on chromosome 4q12, encoding Ras-like protein family member 11B (Q9BPW5).

Predicted to enable G protein activity; GTP binding activity; and transforming growth factor beta receptor binding activity. Predicted to act upstream of or within negative regulation of transforming growth factor beta receptor signaling pathway.

Source: NCBI Gene 65997 — RefSeq curated summary.

At a glance

• GWAS associations: 7
• Clinical variants (ClinVar): 30 total
• MANE Select transcript: NM_023940

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:23804
Approved symbol	RASL11B
Name	RAS like family 11 member B
Location	4q12
Locus type	gene with protein product
Status	Approved
Ensembl gene	ENSG00000128045
Ensembl biotype	protein_coding
OMIM	612404
Entrez	65997

Gene structure

Transcript identifiers

Ensembl transcripts: 3 — 1 protein_coding, 1 protein_coding_CDS_not_defined, 1 retained_intron

ENST00000248706, ENST00000505041, ENST00000515677

RefSeq mRNA: 1 — MANE Select: NM_023940 NM_023940

CCDS: CCDS3490

Canonical transcript exons

ENST00000248706 — 4 exons

Exon	Start	End
ENSE00000916850	52863268	52863324
ENSE00000969361	52862317	52862649
ENSE00000969362	52865335	52866835
ENSE00003570824	52864478	52864554

Expression profiles

Bgee: expression breadth ubiquitous, 155 present calls, max score 93.20.

FANTOM5 (CAGE): breadth broad, TPM avg 2.4599 / max 96.1561, expressed in 538 samples.

FANTOM5 promoters (1 alternative TSS)

Promoter ID	TPM avg	Samples expressed
47614	2.4599	538

Top tissues by expression

245 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
right ovary	UBERON:0002118	93.20	gold quality
left ovary	UBERON:0002119	92.90	gold quality
metanephros cortex	UBERON:0010533	89.30	gold quality
cortical plate	UBERON:0005343	88.59	gold quality
spleen	UBERON:0002106	86.24	gold quality
cerebellar hemisphere	UBERON:0002245	84.63	gold quality
cerebellar cortex	UBERON:0002129	84.55	gold quality
right hemisphere of cerebellum	UBERON:0014890	84.46	gold quality
ovary	UBERON:0000992	84.39	gold quality
male germ line stem cell (sensu Vertebrata) in testis	CL:0000089 ∩ UBERON:0000473	84.16	gold quality
right coronary artery	UBERON:0001625	84.12	gold quality
ganglionic eminence	UBERON:0004023	83.74	gold quality
embryo	UBERON:0000922	83.73	gold quality
stromal cell of endometrium	CL:0002255	83.41	gold quality
prefrontal cortex	UBERON:0000451	83.22	gold quality
Brodmann (1909) area 9	UBERON:0013540	83.17	gold quality
left coronary artery	UBERON:0001626	82.98	gold quality
cerebellum	UBERON:0002037	82.21	gold quality
popliteal artery	UBERON:0002250	81.99	gold quality
tibial artery	UBERON:0007610	81.97	gold quality
right frontal lobe	UBERON:0002810	81.75	gold quality
apex of heart	UBERON:0002098	81.57	gold quality
buccal mucosa cell	CL:0002336	81.16	gold quality
coronary artery	UBERON:0001621	80.77	gold quality
right atrium auricular region	UBERON:0006631	80.24	gold quality
aorta	UBERON:0000947	80.17	gold quality
cardiac atrium	UBERON:0002081	79.23	gold quality
descending thoracic aorta	UBERON:0002345	78.51	gold quality
thoracic aorta	UBERON:0001515	78.29	gold quality
adult mammalian kidney	UBERON:0000082	78.25	gold quality

Single-cell (SCXA)

Detected in 2 experiment(s), a significant marker in 2.

Experiment	Marker?	Max mean expression
E-HCAD-5	yes	18.95
E-ANND-3	yes	13.18

Regulation

Is transcription factor: no

Upstream regulators (CollecTRI, top): GLI1

miRNA regulators (miRDB)

75 targeting RASL11B, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-3163	100.00	77.23	8605
HSA-MIR-493-5P	99.96	72.47	2382
HSA-MIR-2110	99.96	66.68	1930
HSA-LET-7C-3P	99.95	73.42	2862
HSA-MIR-3119	99.92	71.34	2390
HSA-MIR-106A-5P	99.90	73.94	2683
HSA-MIR-3686	99.90	70.53	2432
HSA-MIR-17-5P	99.89	73.83	2665
HSA-MIR-6783-3P	99.89	67.92	2059
HSA-MIR-1343-3P	99.89	66.78	1815
HSA-MIR-106B-5P	99.88	74.72	2795
HSA-MIR-20A-5P	99.88	74.76	2769
HSA-MIR-20B-5P	99.88	74.01	2621
HSA-MIR-519D-3P	99.88	73.97	2607
HSA-MIR-526B-3P	99.88	74.06	2587
HSA-MIR-93-5P	99.88	73.98	2606
HSA-LET-7A-2-3P	99.87	70.53	1921
HSA-MIR-6124	99.87	69.78	3551
HSA-LET-7G-3P	99.85	70.43	1929
HSA-MIR-205-5P	99.81	70.05	1557
HSA-MIR-4668-5P	99.79	70.58	3782
HSA-MIR-1299	99.77	71.24	2389
HSA-MIR-6794-5P	99.76	66.38	1048
HSA-MIR-3156-3P	99.76	66.72	939
HSA-MIR-4255	99.72	67.70	1541
HSA-MIR-4716-3P	99.69	66.73	1022
HSA-MIR-519A-3P	99.67	71.67	1868
HSA-MIR-519B-3P	99.67	71.67	1868
HSA-MIR-519C-3P	99.67	71.67	1870
HSA-MIR-875-3P	99.63	69.47	2548

Literature-anchored findings (GeneRIF, showing 4)

• RASL11B gene is expressed in all tissues investigated, with highest levels in placenta & primary macrophages. RASL11B may play a role in TGF-beta1-mediated developmental processes & in pathophysiologies such as inflammation, cancer, and arteriosclerosis. (PMID:17628721)
• MEG3 could up-regulate RASL11B to inhibit the cell proliferation, invasion, and migration; induce G0/G1 cell cycle arrest; and promote cell apoptosis by suppressing miR-7 in clear cell renal cell carcinoma. (PMID:29968912)
• the present study identified a novel significant association between the increased expression levels of MAPK10, TUBB2B and RASL11B, and neuroblastoma cells. (PMID:31432180)
• RASL11B gene enhances hyaluronic acid-mediated chondrogenic differentiation in human amniotic mesenchymal stem cells via the activation of Sox9/ERK/smad signals. (PMID:32878463)

Cross-species orthologs

3 orthologs

Organism	Symbol	Gene ID
danio_rerio	rasl11b	ENSDARG00000015611
mus_musculus	Rasl11b	ENSMUSG00000049907
rattus_norvegicus	Rasl11b	ENSRNOG00000002097

Paralogs (35): RALA (ENSG00000006451), REM1 (ENSG00000088320), RASL10A (ENSG00000100276), RASD2 (ENSG00000100302), RASL12 (ENSG00000103710), RHEB (ENSG00000106615), RASD1 (ENSG00000108551), RERGL (ENSG00000111404), RAP1A (ENSG00000116473), RASL11A (ENSG00000122035), RAP2C (ENSG00000123728), RAP2A (ENSG00000125249), RRAS (ENSG00000126458), RAP1B (ENSG00000127314), KRAS (ENSG00000133703), RRAS2 (ENSG00000133818), RERG (ENSG00000134533), REM2 (ENSG00000139890), RIT1 (ENSG00000143622), RALB (ENSG00000144118), RIT2 (ENSG00000152214), MRAS (ENSG00000158186), DIRAS3 (ENSG00000162595), GEM (ENSG00000164949), DIRAS2 (ENSG00000165023), RRAD (ENSG00000166592), RHEBL1 (ENSG00000167550), NKIRAS2 (ENSG00000168256), HRAS (ENSG00000174775), DIRAS1 (ENSG00000176490), RAP2B (ENSG00000181467), ERAS (ENSG00000187682), NKIRAS1 (ENSG00000197885), NRAS (ENSG00000213281), RASL10B (ENSG00000270885)

Protein

Protein identifiers

Ras-like protein family member 11B — Q9BPW5 (reviewed: Q9BPW5)

All UniProt accessions (1): Q9BPW5

UniProt curated annotations — full annotation on UniProt →

Tissue specificity. Widely expressed with highest levels in placenta and primary macrophages.

Induction. By TGFB1.

Similarity. Belongs to the small GTPase superfamily. Ras family.

RefSeq proteins (1): NP_076429* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR001806	Small_GTPase	Family
IPR005225	Small_GTP-bd	Domain
IPR027417	P-loop_NTPase	Homologous_superfamily
IPR051065	Ras-related_GTPase	Family

Pfam: PF00071

Catalyzed reactions (Rhea), 1 shown:

• GTP + H2O = GDP + phosphate + H(+) (RHEA:19669)

UniProt features (8 total): binding site 3, region of interest 2, sequence conflict 2, chain 1

Structure

Experimental structures (PDB)

0 structures.

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q9BPW5-F1	79.69	0.52

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Ligand- & substrate-binding residues (3): 40–47; 87–94; 152–155

Function

Pathways and Gene Ontology

Reactome pathways

0 pathways

MSigDB gene sets: 182 (showing top): SHEPARD_BMYB_MORPHOLINO_UP, GOBP_REGULATION_OF_CELLULAR_RESPONSE_TO_GROWTH_FACTOR_STIMULUS, TGCACTT_MIR519C_MIR519B_MIR519A, SHEPARD_CRASH_AND_BURN_MUTANT_UP, GGGTGGRR_PAX4_03, MARTINEZ_RB1_TARGETS_UP, MUELLER_PLURINET, GERY_CEBP_TARGETS, GOBP_REGULATION_OF_TRANSMEMBRANE_RECEPTOR_PROTEIN_SERINE_THREONINE_KINASE_SIGNALING_PATHWAY, YY1_02, GOBP_RESPONSE_TO_TRANSFORMING_GROWTH_FACTOR_BETA, SCHAEFFER_PROSTATE_DEVELOPMENT_12HR_UP, SCHAEFFER_PROSTATE_DEVELOPMENT_48HR_UP, CREIGHTON_ENDOCRINE_THERAPY_RESISTANCE_5, TGANTCA_AP1_C

GO Biological Process (1): negative regulation of transforming growth factor beta receptor signaling pathway (GO:0030512)

GO Molecular Function (7): G protein activity (GO:0003925), transforming growth factor beta receptor binding (GO:0005160), GTP binding (GO:0005525), nucleotide binding (GO:0000166), GTPase activity (GO:0003924), protein binding (GO:0005515), hydrolase activity (GO:0016787)

GO Cellular Component (0):

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
transforming growth factor beta receptor signaling pathway	1
regulation of transforming growth factor beta receptor signaling pathway	1
negative regulation of transmembrane receptor protein serine/threonine kinase signaling pathway	1
GTPase activity	1
molecular function regulator activity	1
cytokine receptor binding	1
guanyl ribonucleotide binding	1
purine ribonucleoside triphosphate binding	1
nucleoside phosphate binding	1
heterocyclic compound binding	1
ribonucleoside triphosphate phosphatase activity	1
binding	1
catalytic activity	1

Protein interactions and networks

STRING

1792 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
RASL11B	ARL9	Q6T311	851
RASL11B	TGFB1	P01137	481
RASL11B	SYDE2	Q5VT97	470
RASL11B	CCDC125	Q86Z20	454
RASL11B	ARRDC2	Q8TBH0	443
RASL11B	RFT1	Q96AA3	431
RASL11B	CNKSR1	Q969H4	423
RASL11B	RHOF	Q9HBH0	410
RASL11B	RASSF1	Q9NS23	380
RASL11B	POLR2B	P30876	377
RASL11B	DEPDC7	Q96QD5	376
RASL11B	GTPBP4	Q9BZE4	372
RASL11B	SLC35E3	Q7Z769	369
RASL11B	ABHD12B	Q7Z5M8	367
RASL11B	LRRC25	Q8N386	364
RASL11B	SPEF1	Q9Y4P9	364

IntAct

128 interactions, top by confidence:

A	B	Type	Score
MAGI1	RASL11B	psi-mi:“MI:0915”(physical association)	0.560
GEMIN6	RASL11B	psi-mi:“MI:0915”(physical association)	0.560
RASL11B	MAGI2	psi-mi:“MI:0407”(direct interaction)	0.440
RASL11B	MAGI3	psi-mi:“MI:0407”(direct interaction)	0.440
RASL11B	MAGI1	psi-mi:“MI:0407”(direct interaction)	0.440
RASL11B	MAST2	psi-mi:“MI:0407”(direct interaction)	0.440
RASL11B	DLG1	psi-mi:“MI:0407”(direct interaction)	0.440
RASL11B	DLG4	psi-mi:“MI:0407”(direct interaction)	0.440
RASL11B	DLG2	psi-mi:“MI:0407”(direct interaction)	0.440
RASL11B	SYNJ2BP	psi-mi:“MI:0407”(direct interaction)	0.440
RASL11B	LNX2	psi-mi:“MI:0407”(direct interaction)	0.440
RASL11B	DLG3	psi-mi:“MI:0407”(direct interaction)	0.440
RASL11B	MAST1	psi-mi:“MI:0407”(direct interaction)	0.440
RASL11B	SNX27	psi-mi:“MI:0407”(direct interaction)	0.440
RASL11B	PDZD7	psi-mi:“MI:0407”(direct interaction)	0.440
RASL11B	ARHGEF12	psi-mi:“MI:0407”(direct interaction)	0.440
RASL11B	PTPN3	psi-mi:“MI:0407”(direct interaction)	0.440
RASL11B	GORASP2	psi-mi:“MI:0407”(direct interaction)	0.440
DLG1	RASL11B	psi-mi:“MI:0407”(direct interaction)	0.440
TAMALIN	RASL11B	psi-mi:“MI:0407”(direct interaction)	0.440
RASL11B	TAX1BP3	psi-mi:“MI:0407”(direct interaction)	0.440
ARHGEF11	RASL11B	psi-mi:“MI:0407”(direct interaction)	0.440
RASL11B	PATJ	psi-mi:“MI:0407”(direct interaction)	0.440
RASL11B	SCRIB	psi-mi:“MI:0407”(direct interaction)	0.440
RASL11B	PDZD2	psi-mi:“MI:0407”(direct interaction)	0.440

BioGRID (21): RASL11B (Two-hybrid), RASL11B (Reconstituted Complex), RASL11B (Reconstituted Complex), MAGI1 (Two-hybrid), GEMIN6 (Two-hybrid), LTF (Affinity Capture-MS), PPM1B (Affinity Capture-MS), PPM1A (Affinity Capture-MS), RAP1GDS1 (Affinity Capture-MS), BPIFA1 (Affinity Capture-MS), MUC5AC (Affinity Capture-MS), SCGB2A1 (Affinity Capture-MS), BPIFB1 (Affinity Capture-MS), RASL11B (Proximity Label-MS), RASL11B (Proximity Label-MS)

ESM2 similar proteins: A1DZY4, A6QP66, O35626, O35929, O88910, O88954, P0C0E4, P35295, P51157, P51158, P53667, P53668, P53669, P55040, P55041, P55043, P63032, P63033, Q06AU5, Q12829, Q13368, Q13637, Q3SWY9, Q5E9J3, Q5FVY2, Q5R541, Q5RFI2, Q6DGN0, Q6IMA3, Q6IMA7, Q6IMB1, Q6P0U3, Q6T310, Q8AVS6, Q8IYK8, Q8QFP8, Q8VEL9, Q8VHP8, Q8VHQ4, Q8WXH6

Diamond homologs: A1DZY4, A6QP66, A8NU18, C4YKT4, O08989, O14807, O35929, O88667, O93856, O94363, P01119, P03967, P08645, P08647, P0CY32, P10114, P10536, P11233, P11234, P15064, P17609, P22124, P22126, P22278, P22279, P22280, P28775, P32254, P36860, P36863, P48555, P59279, P61105, P61225, P61226, P61227, P62070, P62071, P63320, P63321

SIGNOR signaling

0 interactions.

Enriched among interaction partners

Reactome pathways and GO biological processes over-represented among this gene’s 79 IntAct physical interaction partners (hypergeometric vs the genome-wide background, BH-FDR, gene-set size 15–500, ranked by fold). A functional readout of the neighbourhood — distinct from this gene’s own memberships above, and biased toward well-studied / hub proteins, so read it as themes rather than proof.

Reactome pathways:

Pathway	Partners	Fold	FDR
Ras activation upon Ca2+ influx through NMDA receptor	5	57.1×	8e-07
Unblocking of NMDA receptors, glutamate binding and activation	5	54.4×	8e-07
Negative regulation of NMDA receptor-mediated neuronal transmission	5	54.4×	8e-07
Assembly and cell surface presentation of NMDA receptors	10	50.8×	3e-13
Dopamine Neurotransmitter Release Cycle	5	49.6×	1e-06
Long-term potentiation	5	47.6×	1e-06
Neurexins and neuroligins	11	43.3×	1e-13
Protein-protein interactions at synapses	7	37.2×	4e-08

GO biological processes:

GO term	Partners	Fold	FDR
establishment or maintenance of epithelial cell apical/basal polarity	10	76.5×	2e-14
protein localization to synapse	6	60.5×	8e-08
receptor clustering	7	57.5×	6e-09
regulation of postsynaptic membrane neurotransmitter receptor levels	6	39.1×	7e-07
protein-containing complex assembly	9	13.5×	1e-06
cell-cell adhesion	10	13.4×	3e-07
regulation of small GTPase mediated signal transduction	5	9.5×	3e-03
protein localization to plasma membrane	5	7.2×	9e-03

Disease & clinical

Clinical variants and AI predictions

ClinVar

30 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	28
Likely benign	1
Benign	0

Top pathogenic / likely-pathogenic (0)

SpliceAI

337 predictions. Top by Δscore:

Variant	Effect	Δscore
4:52862645:GACCG:G	donor_gain	1.0000
4:52862647:CCG:C	donor_gain	1.0000
4:52862650:G:GG	donor_gain	1.0000
4:52862651:T:G	donor_loss	1.0000
4:52863258:T:A	acceptor_gain	1.0000
4:52863261:C:A	acceptor_gain	1.0000
4:52863262:GTGCA:G	acceptor_loss	1.0000
4:52863263:T:TA	acceptor_gain	1.0000
4:52863263:TGCA:T	acceptor_loss	1.0000
4:52863264:GCA:G	acceptor_loss	1.0000
4:52863265:CAGCA:C	acceptor_loss	1.0000
4:52863266:A:AG	acceptor_gain	1.0000
4:52863266:A:C	acceptor_loss	1.0000
4:52863267:G:A	acceptor_loss	1.0000
4:52863267:G:GA	acceptor_gain	1.0000
4:52863267:GC:G	acceptor_gain	1.0000
4:52863267:GCA:G	acceptor_gain	1.0000
4:52863267:GCAC:G	acceptor_gain	1.0000
4:52863267:GCACT:G	acceptor_gain	1.0000
4:52863322:CAGG:C	donor_loss	1.0000
4:52863323:AGG:A	donor_loss	1.0000
4:52863324:GGTG:G	donor_loss	1.0000
4:52863325:GTGA:G	donor_loss	1.0000
4:52863326:T:A	donor_loss	1.0000
4:52864476:AGG:A	acceptor_loss	1.0000
4:52864477:GGTA:G	acceptor_gain	1.0000
4:52865329:TTTCA:T	acceptor_loss	1.0000
4:52865333:A:AG	acceptor_gain	1.0000
4:52865333:AGG:A	acceptor_loss	1.0000
4:52865334:G:GC	acceptor_gain	1.0000

AlphaMissense

1622 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
4:52862647:C:T	T47I	1.000
4:52863297:T:C	F58L	1.000
4:52863299:C:A	F58L	1.000
4:52863299:C:G	F58L	1.000
4:52865516:A:T	K153I	1.000
4:52865517:A:C	K153N	1.000
4:52865517:A:T	K153N	1.000
4:52865525:T:C	L156P	1.000
4:52862625:G:C	G40R	0.999
4:52862640:G:C	G45R	0.999
4:52862641:G:A	G45D	0.999
4:52862641:G:T	G45V	0.999
4:52863280:G:C	R52P	0.999
4:52863289:C:T	T55I	0.999
4:52863295:G:C	R57P	0.999
4:52863298:T:C	F58S	0.999
4:52863298:T:G	F58C	0.999
4:52864532:T:A	V85D	0.999
4:52865395:G:C	A113P	0.999
4:52865413:T:C	S119P	0.999
4:52865431:A:C	S125R	0.999
4:52865433:C:A	S125R	0.999
4:52865433:C:G	S125R	0.999
4:52865522:A:C	D155A	0.999
4:52865522:A:G	D155G	0.999
4:52865603:C:T	S182F	0.999
4:52862617:C:A	A37D	0.998
4:52862626:G:A	G40D	0.998
4:52862640:G:T	G45C	0.998
4:52862644:A:T	K46M	0.998

dbSNP variants (sampled 300 via entrez): RS1000144761 (4:52862193 G>C,T), RS1000512547 (4:52864301 G>A,T), RS1000515006 (4:52862230 G>A), RS1001113898 (4:52861630 C>G,T), RS1001172840 (4:52862124 T>A,C,G), RS1001292166 (4:52862201 C>A,G,T), RS1001339249 (4:52867214 C>T), RS1001342112 (4:52861960 C>A), RS1002179913 (4:52862799 C>A), RS1002274285 (4:52860985 C>G), RS1002347793 (4:52860729 GGAAA>G), RS1002848056 (4:52861170 C>G), RS1002962628 (4:52861383 G>A,C), RS1004677938 (4:52864714 G>A), RS1004685817 (4:52866601 G>A)

Disease associations

OMIM: gene MIM:612404 | disease phenotypes:

GenCC curated gene-disease

Mondo (0):

Orphanet (0):

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

7 associations (top):

Study	Trait	p-value
GCST003811_5	Response to citalopram or escitalopram and depression	8.000000e-07
GCST009391_395	Metabolite levels	9.000000e-06
GCST009545_4	Moderate or severe prolonged lymphopenia in dimethyl fumarate-treated relapsing-remitting multiple sclerosis	3.000000e-06
GCST010699_75	Brain morphology (min-P)	3.000000e-18
GCST010701_71	Cortical surface area (MOSTest)	2.000000e-09
GCST010702_63	Subcortical volume (MOSTest)	8.000000e-12
GCST010703_102	Brain morphology (MOSTest)	6.000000e-21

EFO canonical traits (2, from GWAS)

EFO ID	Trait name
EFO:0010437	triacylglycerol 58:10 measurement
EFO:0004346	neuroimaging measurement

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

CTD chemical–gene interactions

45 total (human), top 30 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Valproic Acid	affects cotreatment, increases expression, affects expression	7
Benzo(a)pyrene	affects methylation, decreases expression, increases methylation	3
entinostat	increases expression, affects cotreatment	2
Vorinostat	affects cotreatment, increases expression	2
Calcitriol	decreases expression, affects cotreatment	2
Ethinyl Estradiol	decreases expression, affects expression	2
Phenylmercuric Acetate	increases expression, affects cotreatment	2
methylmercuric chloride	increases expression	1
bisphenol A	increases methylation, affects cotreatment	1
lead acetate	increases expression	1
sodium arsenate	increases abundance, increases expression	1
2-methyl-4-isothiazolin-3-one	increases expression	1
trichostatin A	increases expression	1
arsenite	increases methylation	1
sodium arsenite	decreases expression	1
butyraldehyde	increases expression	1
ferrous chloride	decreases expression	1
2,3-bis(3’-hydroxybenzyl)butyrolactone	affects cotreatment, decreases expression	1
M-VAC protocol	increases response to substance	1
beta-methylcholine	affects expression	1
4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide	affects cotreatment, increases expression	1
dorsomorphin	affects cotreatment, increases expression	1
Decitabine	affects expression	1
Sunitinib	increases expression	1
Zoledronic Acid	decreases expression	1
Fulvestrant	affects cotreatment, increases methylation	1
Arsenic	increases abundance, increases expression	1
Cadmium	increases abundance, increases expression	1
Cisplatin	affects expression	1
Copper	affects binding, decreases expression	1

Clinical trials (associated diseases)

0 trials via MONDO — disease-level, not drug-specific.